A total of 1710 EGFR-mutant NSCLC patients with brain metastasis in 18 studies [4–21] were randomly assigned to receive one of the following 10 medications classes: platinum-based chemotherapy, first-generation EGFR-TKI, second-generation EGFR-TKI, third-generation EGFR-TKI, EGFR-TKIs + platinum-based chemotherapy, EGFR-TKIs + SRS/WBRT, deferring SRS/WBRT, WBRT, EGFR-TKIs + anti-vascular endothelial growth factor receptor (anti-VEGFR), and EGFR-TKIs + MET-TKIs. Here, EGFR is linked to non-small cell lung carcinoma.